eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
4/2018
vol. 35
 
Share:
Share:
abstract:
Original paper

The level of proinflammatory cytokines: interleukins 12, 23, 17 and tumor necrosis factor  in patients with metabolic syndrome accompanying severe psoriasis and psoriatic arthritis

Magdalena Pirowska
,
Aleksander Obtułowicz
,
Sylwia Lipko-Godlewska
,
Anna Goździalska
,
Katarzyna Podolec
,
Anna Wojas-Pelc

Adv Dermatol Allergol 2018; XXXV (4):360 –366
Online publish date: 2018/08/21
View full text Get citation
 
Introduction
The incidence of metabolic syndrome is estimated at 15–24% in the general population and at 30–50% in patients with psoriasis. A probable cause of the described correlation is a constant release in chronic dermatosis of proinflammatory cytokines and their influence on individual systems and organs.

Aim
Assessment of the concentration of the proinflammatory cytokines (IL-12, IL-23, IL-17 and TNF-α) in blood serum and their correlation with the intensity of skin lesions, the presence of psoriatic arthritis and the risk of development of obesity and metabolic syndrome.

Material and methods
The concentrations of subunit p70 IL-12, IL-17 and IL-23, and TNF-α in subjects with psoriasis and metabolic syndrome were determined.

Results
The level of the studied cytokines, IL-17, IL-23 and TNF-α was higher in patients diagnosed with psoriasis. Higher levels of IL-17, IL-23 and TNF-α were observed in patients with metabolic syndrome accompanying psoriasis. A higher level of IL-17 and IL-23 was found in sera of patients with psoriatic arthritis in comparison to normal psoriasis.

Conclusions
In the study, a higher level of IL-17 and IL-23 was also shown in patients with psoriatic arthritis in comparison to patients with normal psoriasis. The effectiveness of anti-IL12/23 drugs in psoriatic arthritis is a confirmation of the obtained results of the studies. Additionally, the increased level of IL-17, both in patients with metabolic syndrome and with psoriasis, could indirectly indicate an increased cardiovascular risk in patients with affected joints in comparison to psoriasis affecting only the skin.

keywords:

psoriasis, metabolic syndrome, cytokines

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.